The July 2026 FDA Peptide Decision: What the Advisory Committee Actually Voted On

The FDA's Pharmacy Compounding Advisory Committee (PCAC) met on 23 and 24 July 2026 to evaluate seven peptides nominated for inclusion on the 503A Bulk Drug Substances List. The list identifies substances that licensed pharmacies may use when compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The committee recommended six of the seven. One, emideltide, was voted down.

Where a numeric vote is not shown, the public record reports the outcome without a tally.

This is the part most coverage gets wrong, so it is worth stating precisely.

• It is not approval. The committee advises; the FDA decides.
• It is not binding. The agency may depart from the recommendation entirely.
• Nothing changed legally. No peptide became lawful to sell, prescribe, or consume on the strength of this vote.
• There is no guaranteed timeline. Any change proceeds through proposed rulemaking, a public comment period of roughly 60 to 90 days, and a final determination.

BPC-157 drew the narrowest result of the seven: 8-6 in favour, with one abstention. The FDA's own review team had recommended against listing it, citing an absence of human data for the routes of administration actually proposed by compounders, and raising a mechanistic concern relating to angiogenesis.

We include that here because it is part of the public record. A page that reported only the favourable half of the vote would not be an accurate account of what happened.

• FDA — Pharmacy Compounding Advisory Committee, 23-24 July 2026 meeting
• Buchanan Ingersoll & Rooney — FDA PCAC recommends six peptides for the 503A bulks list
• NCPA — FDA advisory committee nominates six peptides for pharmacies to compound
• FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A